Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facilities.
Eli Lilly sues to change hospital drug discount payments, WSJ reports
Eli Lilly (LLY) has filed a lawsuit against the heads of the Department of Health and Human Services and one of its agencies, seeking a court
Lilly Sues U.S. to Change Hospital Drug Discount Payments
Eli Lilly sued a federal health agency that has blocked the company’s plan to tighten the way it provides lucrative drug discounts to hospitals.Lilly is the second drugmaker this week to go to court over the issue,
Lilly sues US agency over blocking of drug-rebate program
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking the company's plan to change the way it offers drug discounts to hospitals. The case centers on the federal 340B program,
Eli Lilly follows JNJ in suing govt. over 340B drug-discount program
Eli Lilly (NYSE:LLY) has filed a lawsuit over a U.S. health agency's alleged attempts to block its model for offering rebates for drugs supplied under the government's 340B Program, days after its rival Johnson & Johnson (NYSE:JNJ) filed a similar lawsuit.
Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan
Eli Lilly sued the Health Resources and Services Administration (HRSA) for allegedly blocking the pharma giant's proposal to change the manner by which it offers discounts on medicines under the 340B program.
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Three-Stock Lunch: Eli Lilly, Transdigm, & Nvidia
Lee Munson, president and CIO at Portfolio Wealth Advisors, joins CNBC’s ‘Power Lunch’ to discuss outlooks on three stocks: ...
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Conditions are getting a bit more challenging for the drugmaker.
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...
Wolfe sees attractive Eli Lilly opportunity on price drop, starts at Outperform
Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...
Smart toilet, AI platform among tech in use at drugmaker Eli Lilly’s new $42m hub in S’pore
The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.
Reuters3d
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Nov 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results ...
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...
FiercePharma3d
Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...